logo
logo
Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation

NASDAQ•IART
CEO: Dr. Stuart M. Essig Ph.D.
セクター: Healthcare
業種: Medical - Devices
上場日: 1995-08-16
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
連絡先情報
1100 Campus Road, Princeton, NJ, 08540, United States
609-275-0500
www.integralife.com
時価総額
$855.26M
PER (TTM)
-1.7
31.5
配当利回り
--
52週高値
$25.95
52週安値
$10.65
52週レンジ
2%
順位46Top 59.5%
3.5
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 3.5 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$402.06M+5.57%
直近4四半期の推移

EPS

-$0.07-50.00%
直近4四半期の推移

フリーCF

$25.75M-459.59%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Revenue Growth Modest Nine-month revenue reached $1.200B, showing low single-digit growth compared to $1.168B last year.
Goodwill Impairment Charge Recognized $511.4M goodwill impairment expense during Q2 2025, significantly impacting nine-month net loss.
Working Capital Position Improved Working capital increased to $779.5M as of September 30, 2025, driven by 2025 Notes repayment.
Acclarent Integration Progress Acclarent acquisition contributed to revenue growth, enhancing ENT specialty device market position post-closing.

リスク要因

Significant Net Loss Recorded Nine-month net loss widened substantially to $(514.8)M versus $(26.4)M last year, driven by impairment.
Tariff Environment Uncertainty Evolving tariff changes create risks impacting cost of goods sold, demand, and general economic conditions.
Quality System Remediation Ongoing FDA warning letters regarding quality systems require remediation efforts impacting operations and approvals.
Operating Cash Flow Decline Operating cash flow decreased $40.1M for nine months, primarily due to lower net income and inventory increases.

見通し

Braintree Facility Operationalization Anticipate PMA approval for SurgiMend in 2026 following completion and operationalization of Braintree facility.
Advancing Key Product Approvals Pursuing PMA approval for DuraSorb in 2026, continuing clinical trials for two-stage breast reconstruction.
Debt Covenant Management Leverage ratio covenant requirement drops to 4.75 to 1.00 starting Q4 2026, requiring continued compliance.
Focus on Core Growth Pillars Strategy centers on innovating for outcomes, growing internationally, and broadening impact across care pathways.

同業比較

売上高 (TTM)

AdaptHealth Corp.AHCO
$2.85B
-12.7%
Integra LifeSciences Holdings CorporationIART
$1.64B
+5.0%
CONMED CorporationCNMD
$1.37B
+5.2%

粗利益率 (最新四半期)

LifeMD, Inc.LFMD
87.7%
-2.9pp
InMode Ltd.INMD
77.6%
-3.9pp
Establishment Labs Holdings Inc.ESTA
70.1%
+6.2pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
PRAX$6.78B-25.8-66.9%0.1%
ESTA$2.11B-25.9-253.8%77.1%
AHCO$1.44B18.05.1%43.4%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-3.2%
横ばい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年2月24日
|
EPS:$0.80
|
売上高:-
財務レポート
財務データ
全年度
  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年10月30日|
    売上高: $402.06M+5.6%
    |
    EPS: $-0.07-50.0%
    予想を下回る
  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年7月31日|
    売上高: $415.61M-0.6%
    |
    EPS: $-6.33+3856.3%
    予想を下回る
  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月5日|
    売上高: $382.65M+3.7%
    |
    EPS: $-0.33+682.0%
    予想を下回る
  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月25日|
    売上高: $1.61B+4.5%
    |
    EPS: $-0.09-110.4%
    予想を下回る
  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月4日|
    売上高: $380.83M-0.4%
    |
    EPS: $-0.14-158.3%
    予想を下回る
  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年7月29日|
    売上高: $418.18M+9.7%
    |
    EPS: $-0.16-409.5%
    予想を下回る
  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月6日|
    売上高: $368.87M-3.1%
    |
    EPS: $-0.04-114.1%
    予想を下回る
  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月28日|
    売上高: $1.54B-1.0%
    |
    EPS: $0.87-60.1%
    予想を下回る